Clinical trial · Interventional
Comparison of Quality of Recovery (QoR)-15 Scores Between Propofol and Remimazolam Anesthesia
Comparison of Quality of Recovery (QoR)-15 Scores According to the Use of Anesthetics During Total Intravenous Anesthesia in Female Patients Undergoing Thyroid Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Remimazolam is a ultra-short-acting benzodiazepine that is rapidly metabolized in the body by tissue esterase and not accumulates in the body for long periods of infusion. In addition, similar to other benzodiazepines, it is possible to reverse the sedation and anesthetic effects through flumazenil. It has no injection pain and infusion syndrome compared with propofol. There is no study to investigate overall postoperative functional recovery via QoR-15 in patients receiving TIVA using remimazolam. The purpose of this study is to determine whether there is any difference in the quality of postoperative recovery between propofol-based and remimazolam-based total intravenous anesthesia in female patients undergoing thyroidectomy. The QoR-15 questionnaire score, pain, nausea/vomiting, and the frequency of complications are evaluated and compared between the two groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Patients Undergoing Thyroid Surgery for Neoplasm | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Arm II (Remimazolam group) | Drug | — | UNRESOLVED |
| Arm I (Propofol group) | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Propofol group
- description
- Propofol based total intravenous anesthesia
- interventionNames
- Drug: Arm I (Propofol group)
- type
- ACTIVE_COMPARATOR
- label
- Remimazolam group
- description
- Remimazolam based total intravenous anesthesia
- interventionNames
- Drug: Arm II (Remimazolam group)
Primary outcomes (1)
- measure
- postoperative day 1(POD1) Quality of Recovery(QoR)-15 questionnaire score
- timeFrame
- Postoperative day 1
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: •20≤Age≤65 female Open thyroidectomy ASA-PS I-III Exclusion Criteria: * Allergic history of any study drug * Taking any sedative, opioid, or sleep aid drugs * Psychiatric or neurological disorder * BMI\>30 kg/m2 * Pregnancy * Vulnerable patients
References
Publications (0)
Data not yet available